Hookworm Infections Clinical Trial
Official title:
Efficacy and Safety of Emodepside in Adolescents and Adults Infected With Trichuris Trichiura and Hookworm: Randomized Two Stages Phase II Seamless Adaptive Controlled Single-blind Trials
Verified date | June 2023 |
Source | Swiss Tropical & Public Health Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To compare the efficacy and safety of emodepside to that of albendazole (Zentel®) in participants aged 12-60, inclusive, infected with hookworm.
Status | Completed |
Enrollment | 320 |
Est. completion date | April 11, 2023 |
Est. primary completion date | April 11, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Years to 60 Years |
Eligibility | Inclusion Criteria: - Male or female adults aged between 12 and 60 years; - Written and signed informed consent; - Was examined by a study physician before treatment; - Provided two stool samples at baseline; - Hookworm EPG > 48 and at least two Kato-Katz thick smears slides with more than one hookworm eggs. Exclusion Criteria: - Pregnant or lactating and/or planning to become pregnant within three months after drug treatment; - Type 1 and/or 2 diabetes; - Psychiatric disorders; - History of ophthalmological conditions; - Presence or history of major systemic or chronic illnesses, as assessed by a medical doctor, during initial clinical assessment; - Suffers from severe anaemia (Hb < 80 g/l); - Received anthelminthic treatment within past four weeks; - Attending other clinical trials during the study; - Received strong CYP3A4 inducers or inhibitors as well as concomitant treatments that are relevant substrate for CYP3A4 such as clarithromycin, erythromycin and rifampicin; - Received strong P-gp inhibitors as well as concomitant treatments that are relevant substrates for P-gp such as clotrimazole and ritonavir. - Participated in stage I trials of this protocol |
Country | Name | City | State |
---|---|---|---|
Tanzania | Public Health Laboratory Ivo de Carneri | Chake Chake | Pemba |
Lead Sponsor | Collaborator |
---|---|
Jennifer Keiser | Public Health Laboratory Ivo de Carneri |
Tanzania,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cure rate (CR) of emodepside against hookworm | CR will be calculated as the percentage of hookworm egg-positive participants at baseline who become egg-negative after treatment. | In the week between 14 and 21 days post-treatment | |
Secondary | Geometric Mean Egg Reduction Rate (ERR) of the emodepside against hookworm. | Eggs per gram of stool (EPG) will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The egg reduction rate (ERR) is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). Note: in contrast to the publication the "outcome measure" entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)*100). | In the week between 14 and 21 days post-treatment | |
Secondary | CR of emodepside against Trichuris trichiura and Ascaris lumbricoides | CR will be calculated as the percentage of Trichuris trichiura and Ascaris lumbricoides egg-positive participants at baseline who become egg-negative after treatment. | In the week between 14 and 21 days post-treatment | |
Secondary | ERR of the emodepside against Trichuris trichiura and Ascaris lumbricoides. | EPG will be assessed by adding up the egg counts from the quadruplicate Kato-Katz thick smears and multiplying this number by a factor of six. The ERR is calculated as follows: ERR = (1-(geometric mean EPG at follow-up/geometric mean EPG at baseline))*100). Note: in contrast to the publication the "outcome measure" entry mask requires the complementary percentage: (geometric mean at follow-up/geometric mean at baseline)*100). | In the week between 14 and 21 days post-treatment | |
Secondary | Infection status and intensity assessed for at baseline and 14-21 days post-treatment by FECPAK-G2. | At baseline and 14-21 days post-treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT03261596 -
Mebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana
|
Phase 4 | |
Completed |
NCT03527745 -
Albendazole Dose Finding and Pharmacokinetics in Children and Adults
|
Phase 2 | |
Active, not recruiting |
NCT06188715 -
Efficacy and Safety of MOX/ALB Co-administration in SAC
|
Phase 3 | |
Active, not recruiting |
NCT04227834 -
Soil-transmitted Helminth Reinfection Rates After Single and Repeated School Hygiene Education
|
N/A | |
Completed |
NCT04700423 -
Efficacy and Safety of MOX/ALB vs. IVM/ALB Co-administration
|
Phase 2/Phase 3 | |
Completed |
NCT03172975 -
Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection
|
Phase 2 | |
Recruiting |
NCT06184399 -
Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC
|
Phase 2 | |
Completed |
NCT04726969 -
Efficacy and Safety of MOX/ALB Co-administration
|
Phase 3 | |
Completed |
NCT03995680 -
Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm
|
Phase 2 | |
Completed |
NCT05017194 -
Efficacy and Safety of Emodepside in Adults Infected With Trichuris Trichiura and Hookworm
|
Phase 2 | |
Completed |
NCT01163877 -
Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma
|
N/A |